{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T05:25:41Z","timestamp":1791869141480,"version":"4.3.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,12,31]],"date-time":"2022-12-31T00:00:00Z","timestamp":1672444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,31]],"date-time":"2022-12-31T00:00:00Z","timestamp":1672444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Nuffield Department of Population Health, University of Oxford"},{"name":"Health Education England","award":["NIHR301261"],"award-info":[{"award-number":["NIHR301261"]}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"crossref","award":["C8225\/A21133"],"award-info":[{"award-number":["C8225\/A21133"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background and purpose<\/jats:title>\n                <jats:p>To predict treatment-related cardiovascular disease (CVD) and second cancer 30-year absolute mortality risks (AMR<jats:sub>30<\/jats:sub>) for patients with mediastinal Hodgkin lymphoma in a large multicentre radiation oncology network in Ireland.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Material and methods<\/jats:title>\n                <jats:p>This study includes consecutive patients treated for mediastinal lymphoma using chemotherapy and involved site radiotherapy (RT) 2016\u20132019. Radiation doses to heart, left ventricle, cardiac valves, lungs, oesophagus, carotid arteries and female breasts were calculated. Individual CVD and second cancer AMR<jats:sub>30<\/jats:sub> were predicted using Irish background population rates and dose\u2013response relationships.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Forty-four patients with Hodgkin lymphoma were identified, 23 females, median age 28 years. Ninety-eight percent received anthracycline, 80% received 4\u20136 cycles ABVD. Volumetric modulated arc therapy (VMAT)\u2009\u00b1\u2009deep inspiration breath hold (DIBH) was delivered, median total prescribed dose 30\u00a0Gy. Average mean heart dose 9.8\u00a0Gy (range 0.2\u201323.8\u00a0Gy). Excess treatment-related mean AMR<jats:sub>30<\/jats:sub> from CVD was 2.18% (0.79, 0.90, 0.01, 0.13 and 0.35% for coronary disease, heart failure, valvular disease, stroke and other cardiac diseases), 1.07% due to chemotherapy and a further 1.11% from RT. Excess mean AMR<jats:sub>30<\/jats:sub> for second cancers following RT were: lung cancer 2.20%, breast cancer in females 0.34%, and oesophageal cancer 0.28%.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>For patients with mediastinal lymphoma excess mortality risks from CVD and second cancers remain clinically significant despite contemporary chemotherapy and photon-RT. Efforts to reduce the toxicity of combined modality treatment, for example, using DIBH, reduced margins and advanced RT, e.g. proton beam therapy, should be continued to further reduce potentially fatal treatment effects.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12094-022-03034-z","type":"journal-article","created":{"date-parts":[[2022,12,31]],"date-time":"2022-12-31T03:02:43Z","timestamp":1672455763000},"page":"1368-1377","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Predicted cardiac and second cancer risks for patients undergoing VMAT for mediastinal Hodgkin lymphoma"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9199-460X","authenticated-orcid":false,"given":"Orla A.","family":"Houlihan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Ntentas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Cutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Daly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Gillham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orla","family":"McArdle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances K.","family":"Duane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,31]]},"reference":[{"issue":"16","key":"3034_CR1","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","volume":"35","author":"MPE Andr\u00e9","year":"2017","unstructured":"Andr\u00e9 MPE, Girinsky T, Federico M, Reman O, Fortpied C, Gotti M, et al. Early positron emission tomography response\u2013adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial. J Clin Oncol. 2017;35(16):1786\u201394.","journal-title":"J Clin Oncol"},{"issue":"1","key":"3034_CR2","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1182\/asheducation-2016.1.323","volume":"2016","author":"FE van Leeuwen","year":"2016","unstructured":"van Leeuwen FE, Ng AK. Long-term risk of second malignancy and cardiovascular disease after Hodgkin lymphoma treatment. Hematology Am Soc Hematol Educ Program. 2016;2016(1):323\u201330.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"17","key":"3034_CR3","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","volume":"372","author":"J Radford","year":"2015","unstructured":"Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johnson P, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma. N Engl J Med. 2015;372(17):1598\u2013607.","journal-title":"N Engl J Med"},{"issue":"5","key":"3034_CR4","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.ijrobp.2020.03.019","volume":"107","author":"A Wirth","year":"2020","unstructured":"Wirth A, Mikhaeel NG, Aleman BMP, Pinnix CC, Constine LS, Ricardi U, et al. Involved site radiation therapy in adult lymphomas: an overview of international lymphoma radiation oncology group guidelines. Int J Radiat Oncol Biol Phys. 2020;107(5):909\u201333.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"3034_CR5","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa1000067","volume":"363","author":"A Engert","year":"2010","unstructured":"Engert A, Pl\u00fctschow A, Eich HT, Lohri A, D\u00f6rken B, Borchmann P, et al. Reduced treatment intensity in patients with early-stage Hodgkin\u2019s lymphoma. N Engl J Med. 2010;363(7):640\u201352.","journal-title":"N Engl J Med"},{"issue":"4","key":"3034_CR6","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1016\/j.ijrobp.2011.05.015","volume":"82","author":"A Paumier","year":"2012","unstructured":"Paumier A, Ghalibafian M, Gilmore J, Beaudre A, Blanchard P, el Nemr M, et al. Dosimetric benefits of intensity-modulated radiotherapy combined with the deep-inspiration breath-hold technique in patients with mediastinal Hodgkin\u2019s lymphoma. Int J Radiat Oncol Biol Phys. 2012;82(4):1522\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"3034_CR7","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3109\/0284186X.2014.932435","volume":"54","author":"PM Petersen","year":"2015","unstructured":"Petersen PM, Aznar MC, Berthelsen AK, Loft A, Schut DA, Maraldo M, et al. Prospective phase II trial of image-guided radiotherapy in Hodgkin lymphoma: benefit of deep inspiration breath-hold. Acta Oncol. 2015;54(1):60\u20136.","journal-title":"Acta Oncol"},{"key":"3034_CR8","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/1748-717X-7-186","volume":"7","author":"C Fiandra","year":"2012","unstructured":"Fiandra C, Filippi AR, Catuzzo P, Botticella A, Ciammella P, Franco P, et al. Different IMRT solutions vs 3D-conformal radiotherapy in early stage Hodgkin\u2019s lymphoma: dosimetric comparison and clinical considerations. Radiat Oncol. 2012;7:186.","journal-title":"Radiat Oncol"},{"key":"3034_CR9","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/1748-717X-9-94","volume":"9","author":"KR Voong","year":"2014","unstructured":"Voong KR, McSpadden K, Pinnix CC, Shihadeh F, Reed V, Salehpour MR, et al. Dosimetric advantages of a \u201cbutterfly\u201d technique for intensity-modulated radiation therapy for young female patients with mediastinal Hodgkin\u2019s lymphoma. Radiat Oncol. 2014;9:94.","journal-title":"Radiat Oncol"},{"issue":"3","key":"3034_CR10","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.radonc.2018.08.017","volume":"129","author":"A Starke","year":"2018","unstructured":"Starke A, Bowden J, Lynn R, Hall K, Hudson K, Rato A, et al. Comparison of butterfly volumetric modulated arc therapy to full arc with or without deep inspiration breath hold for the treatment of mediastinal lymphoma. Radiother Oncol. 2018;129(3):449\u201355.","journal-title":"Radiother Oncol"},{"key":"3034_CR11","doi-asserted-by":"crossref","unstructured":"Ntentas G, Dedeckova K, Andrlik M, Aznar MC, Shakir R, Ramroth J, et al. Proton therapy in supradiaphragmatic lymphoma: predicting treatment-related mortality to help optimize patient selection. Int J Radiat Oncol Biol Phys. 2022;112(4):913\u201325.","DOI":"10.1016\/j.ijrobp.2021.10.151"},{"issue":"6","key":"3034_CR12","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1001\/jamainternmed.2015.1180","volume":"175","author":"FA van Nimwegen","year":"2015","unstructured":"van Nimwegen FA, Schaapveld M, Janus CP, Krol AD, Petersen EJ, Raemaekers JM, et al. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med. 2015;175(6):1007\u201317.","journal-title":"JAMA Intern Med"},{"issue":"4","key":"3034_CR13","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/j.ijrobp.2013.05.005","volume":"89","author":"L Specht","year":"2014","unstructured":"Specht L, Yahalom J, Illidge T, Berthelsen AK, Constine LS, Eich HT, et al. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG). Int J Radiat Oncol Biol Phys. 2014;89(4):854\u201362.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"3034_CR14","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ijrobp.2009.10.058","volume":"79","author":"M Feng","year":"2011","unstructured":"Feng M, Moran JM, Koelling T, Chughtai A, Chan JL, Freedman L, et al. Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer. Int J Radiat Oncol Biol Phys. 2011;79(1):10\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3034_CR15","volume-title":"Gray's atlas of anatomy","author":"RA Drake","year":"2020","unstructured":"Drake RA, Vogl W, Mitchell A, Tibbitts R, Richardson P. Gray\u2019s atlas of anatomy. 3rd ed. Philadelphia: Elsevier\/Churchill Livingstone; 2020.","edition":"3"},{"key":"3034_CR16","unstructured":"IMAIOS. E-anatomy [Internet]. 2021 [cited 2022 Jul 09]. Available from: https:\/\/www.imaios.com\/en\/e-Anatomy."},{"issue":"3","key":"3034_CR17","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.radonc.2017.01.008","volume":"122","author":"F Duane","year":"2017","unstructured":"Duane F, Aznar MC, Bartlett F, Cutter DJ, Darby SC, Jagsi R, et al. A cardiac contouring atlas for radiotherapy. Radiother Oncol. 2017;122(3):416\u201322.","journal-title":"Radiother Oncol"},{"issue":"1","key":"3034_CR18","first-page":"20200067","volume":"3","author":"OA Houlihan","year":"2021","unstructured":"Houlihan OA, Rangaswamy G, Dunne M, Rohan C, O\u2019Neill L, Chalke S, et al. Deep inspiration breath hold versus free breathing technique in mediastinal radiotherapy for lymphoma. BJR Open. 2021;3(1):20200067.","journal-title":"BJR Open"},{"issue":"32","key":"3034_CR19","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1200\/JCO.21.00408","volume":"39","author":"DJ Cutter","year":"2021","unstructured":"Cutter DJ, Ramroth J, Diez P, Buckle A, Ntentas G, Popova B, et al. Predicted risks of cardiovascular disease following chemotherapy and radiotherapy in the UK NCRI RAPID trial of positron emission tomography\u2013directed therapy for early-stage Hodgkin lymphoma. J Clin Oncol. 2021;39(32):3591\u2013601.","journal-title":"J Clin Oncol"},{"key":"3034_CR20","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1093\/jnci\/djp147","volume":"101","author":"ML De Bruin","year":"2009","unstructured":"De Bruin ML, Dorresteijn LDA, van\u2019t Veer MB, Krol ADG, van der Pal HJ, Kappelle AC, et al. Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma. J Natl Cancer Inst. 2009;101:928\u201337.","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"3034_CR21","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1200\/JCO.2015.63.4444","volume":"34","author":"FA van Nimwegen","year":"2016","unstructured":"van Nimwegen FA, Schaapveld M, Cutter DJ, Janus CP, Krol AD, Hauptmann M, et al. Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma. J Clin Oncol. 2016;34(3):235\u201343.","journal-title":"J Clin Oncol"},{"issue":"16","key":"3034_CR22","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1182\/blood-2016-09-740332","volume":"129","author":"FA van Nimwegen","year":"2017","unstructured":"van Nimwegen FA, Ntentas G, Darby SC, Schaapveld M, Hauptmann M, Lugtenburg PJ, et al. Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines. Blood. 2017;129(16):2257\u201365.","journal-title":"Blood"},{"key":"3034_CR23","doi-asserted-by":"crossref","unstructured":"Cutter DJ, Schaapveld M, Darby SC, Hauptmann M, van Nimwegen FA, Krol ADG, et al. Risk for valvular heart disease after treatment for Hodgkin lymphoma. J Natl Cancer Inst. 2015; 107(4).","DOI":"10.1093\/jnci\/djv008"},{"issue":"2","key":"3034_CR24","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.radonc.2015.01.008","volume":"114","author":"MV Maraldo","year":"2015","unstructured":"Maraldo MV, Lundemann M, Vogelius IR, Specht L. A new method to estimate doses to the normal tissues after past extended and involved field radiotherapy for Hodgkin lymphoma. Radiother Oncol. 2015;114(2):206\u201311.","journal-title":"Radiother Oncol"},{"issue":"3","key":"3034_CR25","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1093\/jnci\/94.3.182","volume":"94","author":"LB Travis","year":"2002","unstructured":"Travis LB, Gospodarowicz M, Curtis RE, Clarke EA, Andersson M, Glimelius B, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin\u2019s disease. J Natl Cancer Inst. 2002;94(3):182\u201392.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"3034_CR26","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1667\/0033-7587(2003)159[0161:LCATFH]2.0.CO;2","volume":"159","author":"ES Gilbert","year":"2003","unstructured":"Gilbert ES, Stovall M, Gospodarowicz M, Van Leeuwen FE, Andersson M, Glimelius B, et al. Lung cancer after treatment for Hodgkin\u2019s disease: focus on radiation effects. Radiat Res. 2003;159(2):161\u201373.","journal-title":"Radiat Res"},{"issue":"22","key":"3034_CR27","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1200\/JCO.2011.38.8835","volume":"30","author":"AJ Swerdlow","year":"2012","unstructured":"Swerdlow AJ, Cooke R, Bates A, Cunningham D, Falk SJ, Gilson D, et al. Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin\u2019s lymphoma in England and Wales: a national cohort study. J Clin Oncol. 2012;30(22):2745\u201352.","journal-title":"J Clin Oncol"},{"issue":"26","key":"3034_CR28","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa1505949","volume":"373","author":"M Schaapveld","year":"2015","unstructured":"Schaapveld M, Aleman BM, van Eggermond AM, Janus CP, Krol AD, van der Maazen RW, et al. Second cancer risk up to 40 years after treatment for Hodgkin\u2019s lymphoma. N Engl J Med. 2015;373(26):2499\u2013511.","journal-title":"N Engl J Med"},{"issue":"10","key":"3034_CR29","doi-asserted-by":"publisher","first-page":"e193","DOI":"10.3324\/haematol.2014.108258","volume":"99","author":"MM Lindsay","year":"2014","unstructured":"Lindsay MM, Ethel SG, Marilyn S, EvL Flora, Gra\u00e7a MD, Charles FL, et al. Risk of esophageal cancer following radiotherapy for Hodgkin lymphoma. Haematologica. 2014;99(10):e193\u20136.","journal-title":"Haematologica"},{"key":"3034_CR30","doi-asserted-by":"publisher","first-page":"8033","DOI":"10.2147\/OTT.S220730","volume":"12","author":"U Ricardi","year":"2019","unstructured":"Ricardi U, Maraldo MV, Levis M, Parikh RR. Proton therapy for lymphomas: current state of the art. Onco Targets Ther. 2019;12:8033\u201346.","journal-title":"Onco Targets Ther"},{"key":"3034_CR31","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.radonc.2019.05.009","volume":"138","author":"M Levis","year":"2019","unstructured":"Levis M, Filippi AR, Fiandra C, De Luca V, Bartoncini S, Vella D, et al. Inclusion of heart substructures in the optimization process of volumetric modulated arc therapy techniques may reduce the risk of heart disease in Hodgkin\u2019s lymphoma patients. Radiother Oncol. 2019;138:52\u20138.","journal-title":"Radiother Oncol"},{"issue":"16","key":"3034_CR32","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1182\/blood-2018-03-837633","volume":"132","author":"BS Dabaja","year":"2018","unstructured":"Dabaja BS, Hoppe BS, Plastaras JP, Newhauser W, Rosolova K, Flampouri S, et al. Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines. Blood. 2018;132(16):1635\u201346.","journal-title":"Blood"},{"issue":"3","key":"3034_CR33","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.prro.2019.01.006","volume":"9","author":"G Ntentas","year":"2019","unstructured":"Ntentas G, Dedeckova K, Andrlik M, Aznar MC, George B, Kube\u0161 J, et al. Clinical intensity modulated proton therapy for Hodgkin lymphoma: which patients benefit the most? Pract Radiat Oncol. 2019;9(3):179\u201387.","journal-title":"Pract Radiat Oncol"},{"key":"3034_CR34","unstructured":"Vries Sd, Haaksma ML, J\u00f3\u017awiak K, Schaapveld M, Hodgson DC, Lugtenburg PJ, et al. Development and validation of risk prediction models for coronary heart disease and heart failure after treatment for Hodgkin lymphoma. J Clin Oncol. 2022; 0(0):JCO.21.02613."}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-022-03034-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-022-03034-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-022-03034-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T17:32:39Z","timestamp":1682011959000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-022-03034-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,31]]},"references-count":34,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["3034"],"URL":"https:\/\/doi.org\/10.1007\/s12094-022-03034-z","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,31]]},"assertion":[{"value":"6 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the St Luke\u2019s Radiation Oncology Network ethics committee and was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval (Research involving human participants and\/or animals)"}},{"value":"No informed consent is required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}